References
- Sorensen HT, et al. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark. J Clin Epidemiol. 2003;56:88–93.
- Day CP, James OF, Butler TJ, et al. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet. 1993;341:1423–1428.
- Kim SM, George B, Alcivar-Franco D, et al. QT prolongation is associated with increased mortality in end stage liver disease. World J Cardiol. 2017;9(4):347–354.
- Biselli M, Gramenzi A, Lenzi B, et al. Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2019;17(7):1388–1397 e1381.
- Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int. 2003;23(4):243–248.
- Wong F, Watson H, Gerbes A, et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut. 2012;61(1):108–116.
- Zambruni A, DI Micoli A, Lubisco A, et al. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol. 2007;18(1):77–82.
- Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatol. 1998;27(1):28–34.
- Bernardi M, Maggioli C, Dibra V, et al. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert Rev Gastroenterol Hepatol. 2012;6(1):57–66.